Exelixis Signs Zebrafish Gene Function Deal with AVI BioPharma | GenomeWeb

NEW YORK, April 27 – Exelixis and AVI BioPharma have agreed to partner in a drug development alliance using Exelixis’ zebrafish functional genomics technologies and AVI’s antisense agents, the companies said Friday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.